Drug Trial Radar · NCT05096364
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Apr 28, 2021
Primary completion
Feb 3, 2023
Study completion Feb 3, 2023
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
AK111/PlaceboBiological
After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who achieve Psoriasis Area and Severity Index (PASI) 90 response or higher at week 12Time frame: At week 12
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
AkesoBio Investigative Site 1011
Bengbu, Anhui, China
AkesoBio Investigative Site 1009
Beijing, Beijing Municipality, China
AkesoBio Investigative Site 1016
Beijing, Beijing Municipality, China
AkesoBio Investigative Site 1003
Guangzhou, Guangdong, China
AkesoBio Investigative Site 1007
Guangzhou, Guangdong, China
AkesoBio Investigative Site 1012
Chengde, Hebei, China
AkesoBio Investigative Site 1018
Harbin, Heilongjiang, China
AkesoBio Investigative Site 1008
Changsha, Hunan, China
AkesoBio Investigative Site 1013
Yancheng, Jiangsu, China
AkesoBio Investigative Site 1001
Shanghai, Shanghai Municipality, China
AkesoBio Investigative Site 1010
Shanghai, Shanghai Municipality, China
AkesoBio Investigative Site 1002
Hanzhou, Zhejiang, China
AkesoBio Investigative Site 1006
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.